Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Frontage Holdings Corp. ( (HK:1521) ) has provided an announcement.
Frontage Holdings reported a sharp turnaround in the first quarter of 2026, posting unaudited net profit of about US$2.9 million on revenue of US$67.9 million, compared with a loss a year earlier as sales rose 18.9%. Adjusted net profit surged 212.5% to roughly US$5.0 million, reflecting stronger market demand, operating efficiencies from lean initiatives and incremental contributions from newly consolidated Teddy Clinical Research Laboratory in Shanghai.
The company said economies of scale and improved margins underpinned the earnings rebound, while its unaudited consolidated net assets increased to about US$351.8 million from US$334.6 million at year-end 2025. Management cautioned that the figures are based on internal unaudited accounts and may be subject to adjustments, and advised shareholders and potential investors to act carefully when trading the company’s shares.
More about Frontage Holdings Corp.
Frontage Holdings Corporation is a contract research organization providing laboratory and clinical development services to pharmaceutical and biotechnology clients. The group focuses on preclinical and clinical research support, with operations linked to controlling shareholder Hangzhou Tigermed Consulting, and serves global drug development markets.
Average Trading Volume: 119,764
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.02B
For a thorough assessment of 1521 stock, go to TipRanks’ Stock Analysis page.